Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi 
Introduction
During the initiation of a prevention of mother-to-child transmission of HIV (PMTCT) in Thyolo district of rural Malawi (where both exclusive breast and artificial feeding are available as infant feeding options) group discussions were held with mothers and village elders, and a key issue of concern was 'how breast milk suppression would be achieved in those who chose the artificial feeding option?'. We were made to understand that engorged and dripping breasts were social taboos as it is believed to induce future illnesses in the mother and child. Mothers seen with such breasts thus run the risk of being compelled by household members to allow the newborn to suck on the breasts. This practice constitutes a potential risk due to mixed feeding among those who choose artificial feeding but have delays in breast milk suppression in the early post-natal period.
Although current Malawi and World Health Organization guidelines recommend minimal breast compression for suppressing physiological lactation, we felt this strategy would be inappropriate in our setting and that mothers needed a more effective and rapid alternative. 1, 2 In the industrialized world, the drug cabergoline, administered in a single oral-dose is used for inhibiting physiological lactation. 3, 4 The drug is a prolactin inhibitor and acts by stopping the brain from making and releasing the hormone 'prolactin' from the pituitary gland. When used immediately after delivery it prevents the 'onset' of normal lactation. There are, however, no published reports on the use of this drug among mothers in Africa.
We report on the acceptability, effectiveness and safety of cabergoline for routine lactational suppression in rural Malawi.
Methods
This study was conducted in Thyolo, a rural area of southern Malawi with approximately 550,000 inhabitants. The study was conducted over an eight-week period in early 2004 and included consecutive HIV-positive mothers who opted for the breast feeding option. The main public hospital (Thyolo Hospital) was the site of the study and the procedures and steps for PMTCT in this hospital have been described previously. 5 For mothers choosing the artificial feeding option, cabergoline was offered in a single oral-dose of 1 mg to be taken in the delivery room. Contraindications included a history of hypersensitivity to ergot alkaloids or bromocriptine, toxaemia of pregnancy and essential hypertension. Side-effects were monitored clinically and mothers were interviewed and examined on day 1, 2 and 3 post-partum. Specific symptoms sought for included nausea, vomiting, epigastric pain, breast pain, dizziness, palpitations and visual defects. The pulse rate, blood pressure and vision were examined.
The PMTCT register and an additional pre-tested questionnaire were used to gather information related to the study. Data was analysed using epiinfo 6.4 (Centers for Disease Control, Atlanta, USA). Ethical approval was received from the ethical review boards of both the Ministry of Health of Malawi and Medecins Sans Frontieres.
Results
A total of 104 HIV-positive mothers received cabergoline of whom six declined to participate in the study as they preferred to leave the hospital the day after delivery. Of the 98 mothers (median age 26 years) for whom data is available, the great majority (90%) came from villages. Median parity was 4 (range 1-8), 90% were married and the average educational level was 3.9 years in school. Table 1 summarizes the findings related to acceptability and effectiveness. Four (4%) mothers experienced minor side-effects: of these, two (2%) complained of dizziness after administration and two (2%) experienced epigastric pain, both of which cleared before discharge on the third day after delivery.
Discussion
This study shows that a single oral-dose of cabergoline is safe, effective and highly acceptable for suppressing puerperal lactation. This is one of the first reports on the use of cabergoline in sub-Saharan Africa. When compared to minimal breast compression there are a number of potential operational advantages of using this drug.
First, transmission of the HIV virus through breast feeding accounts for one-third to one-half of all mother-to-child HIV transmission (MTCT) -this risk remains unaffected by peri-partum antiretroviral drug prophylaxis. 6 In settings where exclusive artificial feeding is feasible and safe, administration of this drug in the maternity is safe and easy (single oral-dose) and results in rapid suppression of lactation. This intervention, unlike breast compression 1 which can take as long as three to seven days, is not associated with painful breast engorgements or added health risks on breast health and, because it is so convenient, is clearly more 'mother friendly'.
Second, the cumulative probability of the child acquiring HIV is related to episodes of mixed feeding and breast health problems, particularly mastitis. 6, 7 As suppression of puerperal lactation with cabergoline is relatively abrupt, the 
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Tropical Doctor January 2008, 38 potential risk for mixed feeding -particularly mastitis (associated with engorged breasts) -is avoided. Third, in settings such as ours, where social taboos linked to engorged and dripping breasts may be of concern, the use of a rapid and effective option for breast milk suppression is likely to minimize the social pressure on mothers and facilitate empowerment.
Finally, the drug is likely to be useful for 'weaning' among those who opt for exclusive breast feeding, as transition from breast milk to other feeds can often be relatively abrupt. A dried-up breast will avoid the possibility of feeding with breast milk and other feeds for greater than one day, and this might favourably impact upon HIV-transmission.
About one in three mothers in our setting were aware of other methods of breast milk suppression, namely traditional medicine or breast compression. Although breast compression is recommended for suppression of lactation in resource-limited settings, 1,2 this method had low acceptability, and, in the absence of cabergoline, the great majority of mothers would have resorted to using traditional medicine.
In resource-limited countries such as Malawi, the focus of preventive MTCT has so far been on limiting the risk of MTCT transmission around the time of delivery. However there is a need to minimize the substantial HIV-transmission that is still occurring through breast feeding. Cabergoline is an acceptable, safe and effective drug that could be of significant operational benefit in PMTCT programmes.
Introduction
Epilepsy is one of the most common neurological illnesses. 1 Epileptics comprise 1% of the Pakistani population and most sufferers are under 19 years old. 2 Negative attitudes toward epilepsy are prevalent across the globe. Often the social stigma associated with epilepsy becomes a greater handicap than the associated seizures or the side-effects of medication. 3, 4 Negative attitudes arise from misconceptions and lack of knowledge about the illness. A study by Qidwai et al. 5 assessed the prevalence of myths and fallacies regarding various health issues among patients visiting a family medical centre in Pakistan. Only two questions were asked about epilepsy: 13% believed that evil spirits could cause epilepsy, while 73% thought that psychological stress could do so. No other study assessing the misconceptions regarding this illness in Pakistan has been published. Identification of local misconceptions is important in order to increase awareness and improve attitudes towards epilepsy. Our study examines the various myths and fallacies regarding epilepsy among residents of a Karachi slum area.
